Liver involvement in children with ciliopathies
1Swiss Center for Liver Disease in Children, Department of Pediatrics, University Hospitals of Geneva, 5, rue Willy-Donze, 1205 Geneva, Switzerland.
Clinics and Research in Hepatology and Gastroenterology
|June 24, 2014
Summary
Primary cilia are vital cellular structures. Abnormalities in these cilia, known as ciliopathies, can affect multiple organs, including the liver, leading to conditions like congenital hepatic fibrosis.
Area of Science:
- Cell Biology
- Genetics
- Developmental Biology
Background:
- Primary cilia are crucial cellular organelles involved in signaling pathways.
- Dysfunction of primary cilia underlies a class of genetic disorders known as ciliopathies.
- These disorders often exhibit multi-organ involvement due to the widespread presence of primary cilia.
Purpose of the Study:
- To investigate the role of primary cilia in cholangiocytes.
- To understand the link between primary ciliary abnormalities and liver fibrotic diseases.
- To elucidate the pathogenesis of ductal plate malformation in the context of ciliopathies.
Main Methods:
- Utilizing genetic models with targeted primary cilia defects in cholangiocytes.
- Employing histological and molecular analyses of liver tissues.
- Correlating ciliary structure and function with disease phenotypes.
Main Results:
- Primary ciliary dysfunction in cholangiocytes directly causes ductal plate malformation.
- This malformation is a key event in the development of congenital hepatic fibrosis and Caroli disease/syndrome.
- Specific molecular pathways affected by ciliary defects were identified.
Conclusions:
- Primary cilia in cholangiocytes are essential for normal bile duct development.
- Abnormalities in these cilia are a direct cause of fibrocystic liver diseases.
- Targeting primary cilia dysfunction may offer therapeutic strategies for ciliopathies affecting the liver.
Related Concept Videos
01:26Diseases of the Liver and Gallbladder
2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
01:24Cirrhosis II: Pathophysiology
34
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
34
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
405
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
380
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
380
01:22Lysosomal Hydrolases
3.5K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.5K